Cantor Fitzgerald Reiterates Overweight on Cytokinetics, Maintains $59 Price Target
Portfolio Pulse from richadhand@benzinga.com
Cantor Fitzgerald analyst Charles Duncan has reiterated an Overweight rating on Cytokinetics (NASDAQ:CYTK) and maintained a $59 price target.
August 22, 2023 | 1:42 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Cantor Fitzgerald has reiterated an Overweight rating on Cytokinetics and maintained a $59 price target, which could positively impact the stock.
Analyst ratings and price targets can significantly influence investor sentiment and stock prices. The reiteration of an Overweight rating and a maintained price target of $59 by Cantor Fitzgerald suggests a positive outlook for Cytokinetics, which could lead to an increase in its stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100